What is it about?
Antiphospholipid syndrome (APS) is associated with greater atherothrombotic risk and endothelial dysfunction, suggesting that endothelial glycocalyx is impaired in this disease
Featured Image
Why is it important?
The aim was to investigate the endothelial glycocalyx and the relationship between glycocalyx markers, endothelial dysfunction parameters and atherosclerotic markers in APS
Perspectives
This preliminary study supports, for the first time, that in APS patients endothelial glycocalyx is impaired, which could lead to thrombosis, endothelial dysfunction and early atherosclerosis
Paul Billoir
Rouen University Hospital Vascular Hemostasis Unit
Read the Original
This page is a summary of: New insights into antiphospholipid-related endothelial dysfunction by assessment of vascular glycocalyx layer: results from a preliminary cross-sectional study, Lupus, January 2020, SAGE Publications,
DOI: 10.1177/0961203319897958.
You can read the full text:
Contributors
The following have contributed to this page
